Moreover, the adiponentin–adiponectin receptor 1 (AdipoR1) axis may serve as a predictor of tyrosine kinase inhibitor response and could be a potential therapeutic target in the future treatment of metastatic cancers. The gene discussed is ADIPOR1; the disease is metastatic malignant neoplasm.